Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Anixa Biosciences, Inc.NASDAQ: ANIX
Research & Development · Q2 FY2026 · quarter ended Apr 2026
Research & development declines year over year
Q2 FY2026 research & development of $1.26M fell 4.8% year over year, ahead of the -27.4% change in trailing-twelve-month research & development. Sequentially, it rose 14.2% from the prior quarter. Over 3 fiscal years it compounded at -8.9% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -4.8% holds above the trailing-twelve-month pace of -27.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.07M USD
- Year-over-year change
- -20.7%
- 4-year CAGR
- -4.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 5.07M | -20.7% |
| FY2024 | 2024-10-31 | 6.4M | +34.1% |
| FY2023 | 2023-10-31 | 4.77M | -28.9% |
| FY2022 | 2022-10-31 | 6.7M | +8.3% |
| FY2021 | 2021-10-31 | 6.19M | — |
Research & Development vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 research & development of $4.56M is the lowest of the 10 companies compared; the peer median is $33.44M.
- Its year-over-year change of -27.4% is the 7th highest of 10, against a peer median of -11.2%.
- Over three fiscal years its annual growth of -8.9% compares with a peer median of -2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $96.1M | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $51.51M | -27.2% | -33.9% | — | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $27.77M | -70.1% | -6.9% | 50.7% | |
| LTM Mar 2026 | $21.18M | +82.5% | +30.2% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $9.64M | -35.9% | -14.4% | — |
| LTM Mar 2026 | $7.12M | +45.6% | +1.3% | — | |
| LTM Apr 2026 | $4.56M | -27.4% | -8.9% | — | |
| Peer median (excluding ANIX) | $33.44M | -11.2% | -2.5% | 162.8% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 512K | 0 | 210K | 0 | 0 |
| Cost of Revenue | 385K | 0 | 161K | 0 | 36K |
| Gross Profit | 127K | 0 | 49K | 0 | (36K) |
| Gross Margin | 24.8% | — | 23.3% | — | — |
| Research & Development | 6.19M | 6.7M | 4.77M | 6.4M | 5.07M |
| Selling, General & Admin | 7.07M | 7.17M | 6.29M | 7.44M | 6.63M |
| Operating Expenses | 13.26M | 13.88M | 11.06M | 13.83M | 11.67M |
| Depreciation & Amortization | 59.86K | 42K | 46K | 37K | 36K |
| EBITDA | (13.08M) | (13.73M) | (9.88M) | (12.66M) | (10.99M) |
| EBITDA Margin | -2554.9% | — | -4706.7% | — | — |
| Operating Income | (13.14M) | (13.88M) | (11.01M) | (13.83M) | (11.7M) |
| Operating Margin | -2565.6% | — | -5243.3% | — | — |
| Interest Income | 2.32K | 104K | 1.08M | 1.13M | 673K |
| Interest Expense | 322 | 104K | 0 | 0 | 0 |
| Other Income / Expenses | 7.77K | 104K | 1.08M | 1.13M | 673K |
| Income Before Tax | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Pre-Tax Margin | -2564.0% | — | -4728.6% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.95M) | (13.6M) | (9.81M) | (12.55M) | (10.93M) |
| Net Margin | -2528.6% | — | -4671.9% | — | — |
| EPS (Basic) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| EPS (Diluted) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| Weighted Avg Shares | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
| Weighted Avg Shares (Diluted) | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.